Immunome Inc. (IMNM) shareholders
Close on Nov 17, 2026Market cap $1.95BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19,676,883 | 17.40% | 13G (passive) amendment | Jun 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (15.00%) | 13,056,709 | 15.00% | 13G (passive) amendment | Sep 30, 2025 |
| Alex Silverstein Joint filing with Sirenia Capital Management LP (6.10%) | 6,895,000 | 6.10% | 13G (passive) | Mar 31, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (7.10%) | 6,167,666 | 7.10% | 13G (passive) | Jun 30, 2025 |
| Vanguard Capital Management | 5,725,578 | 5.04% | 13G (passive) | Sep 30, 2026 |
| Jeremy C. Green Joint filing with Redmile Group, LLC (5.20%) | 5,718,385 | 5.20% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 3,981,782 | 6.60% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMNM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19,676,883 | 17.32% | $416.95M | +3,312,872 | 0.27% |
| FMR LLC | 16,987,553 | 14.96% | $359.97M | +17,599 | 0.02% |
| BlackRock, Inc. | 8,805,492 | 7.75% | $186.59M | +636,818 | 0.00% |
| State Street Corp | 5,494,625 | 4.84% | $116.43M | +94,724 | 0.00% |
| Wellington Management Group Llp | 5,210,216 | 4.59% | $110.40M | +478,239 | 0.02% |
| Redmile Group, LLC | 4,911,590 | 4.32% | $104.08M | −647,295 | 6.99% |
| Primecap Management Co/Ca/ | 4,581,431 | 4.03% | $97.08M | −206,800 | 0.06% |
| Vanguard Capital Management LLC | 4,551,289 | 4.01% | $96.44M | +121,592 | 0.00% |
| Driehaus Capital Management LLC | 4,346,139 | 3.83% | $92.09M | +246,238 | 0.53% |
| Enavate Sciences Gp, LLC | 3,613,799 | 3.18% | $76.58M | – | 22.17% |
| Geode Capital Management, LLC | 2,754,889 | 2.43% | $58.39M | +194,225 | 0.00% |
| Morgan Stanley | 2,407,942 | 2.12% | $51.02M | −433,647 | 0.00% |
| Silverarc Capital Management, LLC | 2,017,009 | 1.78% | $42.74M | +166,731 | 4.44% |
| JPMorgan Chase & Co | 1,848,548 | 1.63% | $38.99M | −929,288 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 1,773,229 | 1.56% | $37.58M | −1,085,634 | 0.00% |
| Sofinnova Investments, Inc. | 1,720,316 | 1.51% | $36.45M | +18,412 | 1.88% |
| Readystate Asset Management LP | 1,605,820 | 1.41% | $34.03M | +303,958 | 1.16% |
| Goldman Sachs Group Inc | 1,512,489 | 1.33% | $32.05M | +411,013 | 0.00% |
| Vanguard Portfolio Management LLC | 1,348,979 | 1.19% | $28.58M | +342,004 | 0.00% |
| Principal Financial Group Inc | 1,347,358 | 1.19% | $28.55M | −29,509 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 202 | 118M | 100.0% | 32 / 77 | 60 / 27 | 11M | 9M |
| Q1 2026 | 202 | 117M | 100.0% | 50 / 74 | 48 / 27 | 23M | 20M |
| Q4 2025 | 183 | 120M | 100.0% | 50 / 78 | 36 / 19 | 38M | 10M |
| Q3 2025 | 153 | 91M | 80.5% | 27 / 64 | 38 / 15 | 17M | 5M |
| Q2 2025 | 142 | 79M | 69.9% | 27 / 54 | 39 / 26 | 11M | 9M |
| Q1 2025 | 142 | 77M | 67.8% | 40 / 70 | 16 / 17 | 26M | 2M |
| Q4 2024 | 120 | 53M | 46.9% | 33 / 38 | 35 / 27 | 8M | 6M |
| Q3 2024 | 115 | 52M | 45.5% | 22 / 43 | 29 / 19 | 11M | 4M |
| Q2 2024 | 114 | 48M | 42.6% | 39 / 38 | 23 / 27 | 18M | 7M |
| Q1 2024 | 103 | 38M | 33.0% | 57 / 29 | 11 / 11 | 17M | 1M |
| Q4 2023 | 57 | 22M | 19.1% | 27 / 16 | 6 / 5 | 20M | 1M |
| Q3 2023 | 35 | 3M | 2.4% | 9 / 6 | 10 / 9 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
210 funds held IMNM in Q2 2026, 26% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IMNM | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 7,179,563 | 6.32% | $152.13M | 1.64% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 4,740,888 | 4.17% | $103.49M | 0.10% | May 31, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 3,907,378 | 3.44% | $82.80M | 1.65% | Jun 30, 2026 |
| Vanguard Health Care Fund | 3,703,461 | 3.26% | $84.29M | 0.22% | Jul 31, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 3,692,941 | 3.25% | $84.05M | 1.14% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 3,224,392 | 2.84% | $68.32M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,991,978 | 2.63% | $63.40M | 0.59% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,745,354 | 2.42% | $58.17M | 0.07% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 2,131,664 | 1.88% | $46.53M | 0.88% | May 31, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 1,625,302 | 1.43% | $34.44M | 0.33% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 1,363,778 | 1.20% | $29.77M | 0.11% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 1,242,297 | 1.09% | $27.12M | 0.11% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 1,224,216 | 1.08% | $25.94M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,152,768 | 1.01% | $26.24M | 0.08% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,092,814 | 0.96% | $23.16M | 0.19% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Clay B. Siegall | President and CEO, Director | 870,704 | 0.77% | Jul 27, 2026 |
| Jack Higgins | Chief Scientific Officer | 81,250 | 0.07% | Sep 15, 2026 |
| Kinney Horn | CHIEF BUSINESS OFFICER | 0 | – | Aug 6, 2026 |
| Max Rosett | Chief Financial Officer | 101,287 | 0.09% | Jul 27, 2026 |
| Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | 43,805 | 0.04% | Jul 27, 2026 |
| Philip Tsai | Chief Technical Officer | 81,550 | 0.07% | Jul 27, 2026 |
| Robert Lechleider | Chief Medical Officer | 69,805 | 0.06% | Jul 27, 2026 |
| Isaac Barchas | Director | 92,211 | 0.08% | Aug 12, 2026 |
| Sandra M. Swain | Director | – | – | Jun 12, 2026 |
| Philip Wagenheim | Director | 1,168,787 | 1.03% | Jun 12, 2026 |
| Carol Schafer | Director | – | – | Jun 12, 2026 |
| James P. Boylan | Director | – | – | Jun 12, 2026 |
| Jean Jacques Bienaime | Director | 43,415 | 0.04% | Jun 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jack Higgins Chief Scientific Officer | Sep 11, 2026 | Option exercise | +18,000 | $1.35 | $24.30K | 78,250 |
| Jack Higgins Chief Scientific Officer | Sep 11, 2026 | Sale(10b5-1 plan) | −13,200 | $25.32 | $334.22K | 65,050 |
| Jack Higgins Chief Scientific Officer | Sep 11, 2026 | Gift | −8,800 | – | – | 56,250 |
| Isaac Barchas Director | Aug 12, 2026 | Sale(10b5-1 plan) | −11,048 | $27.25 | $301.06K | 92,211 |
| Isaac Barchas Director | Aug 11, 2026 | Sale(10b5-1 plan) | −62,291 | $26.23 | $1.63M | 0 |
| Isaac Barchas Director | Aug 10, 2026 | Sale(10b5-1 plan) | −10,125 | $26.07 | $263.96K | 62,291 |
| Isaac Barchas Director | Aug 7, 2026 | Sale(10b5-1 plan) | −15,248 | $26.06 | $397.36K | 72,416 |
| Isaac Barchas Director | Aug 6, 2026 | Sale(10b5-1 plan) | −20,840 | $26.06 | $543.09K | 87,664 |
| Kinney Horn CHIEF BUSINESS OFFICER | Aug 4, 2026 | Sale(10b5-1 plan) | −90,616 | $25.09 | $2.27M | 0 |
| Kinney Horn CHIEF BUSINESS OFFICER | Aug 4, 2026 | Option exercise | +50,366 | $12.92 | $650.73K | 50,366 |
| Kinney Horn CHIEF BUSINESS OFFICER | Aug 4, 2026 | Option exercise | +40,250 | $10.60 | $426.65K | 90,616 |
| Kinney Horn CHIEF BUSINESS OFFICER | Jul 23, 2026 | Award | +31,250 | – | – | 31,250 |
| Clay B. Siegall President and CEO, Director | Jul 23, 2026 | Award | +180,000 | – | – | 870,704 |
| Max Rosett Chief Financial Officer | Jul 23, 2026 | Award | +47,250 | – | – | 101,287 |
| Sandra G. Stoneman CHIEF LEGAL OFFICER & GC | Jul 23, 2026 | Award | +38,250 | – | – | 43,805 |
| Philip Tsai Chief Technical Officer | Jul 23, 2026 | Award | +38,250 | – | – | 81,550 |
| Jack Higgins Chief Scientific Officer | Jul 23, 2026 | Award | +38,250 | – | – | 60,250 |
| Robert Lechleider Chief Medical Officer | Jul 23, 2026 | Award | +54,000 | – | – | 69,805 |
| Kinney Horn CHIEF BUSINESS OFFICER | Jul 7, 2026 | Sale(10b5-1 plan) | −1,092 | $25.00 | $27.30K | 0 |
| Kinney Horn CHIEF BUSINESS OFFICER | Jul 7, 2026 | Option exercise | +1,092 | $12.92 | $14.11K | 1,092 |
| Isaac Barchas Director | Jul 7, 2026 | Sale(10b5-1 plan) | −16,906 | $24.20 | $409.13K | 108,504 |
| Isaac Barchas Director | Jul 6, 2026 | Sale(10b5-1 plan) | −83,094 | $24.11 | $2.00M | 125,410 |
| Robert Lechleider Chief Medical Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −22,714 | $21.95 | $498.57K | 48,091 |
| Robert Lechleider Chief Medical Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −16,214 | $22.76 | $369.03K | 31,877 |
| Robert Lechleider Chief Medical Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −16,072 | $23.44 | $376.73K | 15,805 |
| Robert Lechleider Chief Medical Officer | Jul 2, 2026 | Option exercise | +55,000 | $8.73 | $480.15K | 70,805 |
| Isaac Barchas Director | Jul 2, 2026 | Sale(10b5-1 plan) | −24,335 | $23.33 | $567.74K | 208,504 |
| Isaac Barchas Director | Jul 2, 2026 | Sale(10b5-1 plan) | −75,665 | $22.35 | $1.69M | 232,839 |
| Isaac Barchas Director | Jun 30, 2026 | Sale(10b5-1 plan) | −101,050 | $21.12 | $2.13M | 308,504 |
| Robert Lechleider Chief Medical Officer | Jun 25, 2026 | Sale(10b5-1 plan) | −14,420 | $20.66 | $297.92K | 15,805 |
| Robert Lechleider Chief Medical Officer | Jun 25, 2026 | Option exercise | +55,000 | $8.73 | $480.15K | 70,805 |
| Robert Lechleider Chief Medical Officer | Jun 25, 2026 | Sale(10b5-1 plan) | −40,580 | $19.56 | $793.74K | 30,225 |
| Max Rosett Chief Financial Officer | Jun 15, 2026 | Option exercise | +60,000 | $1.05 | $63.00K | 114,037 |
| Max Rosett Chief Financial Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −60,000 | $18.23 | $1.09M | 54,037 |
| Jean Jacques Bienaime Director | Jun 5, 2026 | Buy | +1,000 | $19.27 | $19.27K | 43,415 |
| Jean Jacques Bienaime Director | Jun 5, 2026 | Buy | +3,500 | $19.46 | $68.11K | 42,415 |
| Jean Jacques Bienaime Director | Jun 5, 2026 | Buy | +6,000 | $19.48 | $116.88K | 38,915 |
| Jean Jacques Bienaime Director | Jun 5, 2026 | Sale | −10,000 | $19.41 | $194.10K | 32,915 |
| Jean Jacques Bienaime Director | Jun 5, 2026 | Sale | −500 | $19.44 | $9.72K | 42,915 |
| Jean Jacques Bienaime Director | May 15, 2026 | Buy | +5,000 | $20.70 | $103.50K | 43,415 |
| Max Rosett Chief Financial Officer | Apr 2, 2026 | Option exercise | +31,848 | $1.05 | $33.44K | 79,324 |
| Max Rosett Chief Financial Officer | Apr 2, 2026 | Option exercise | +39,713 | $1.35 | $53.61K | 119,037 |
| Max Rosett Chief Financial Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −63,656 | $21.91 | $1.39M | 55,381 |
| Max Rosett Chief Financial Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −1,344 | $22.48 | $30.21K | 54,037 |
| Jack Higgins Chief Scientific Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −9,438 | $21.64 | $204.24K | 22,000 |
| Jack Higgins Chief Scientific Officer | Mar 30, 2026 | Gift | −6,291 | – | – | 31,438 |
| Clay B. Siegall President and CEO, Director | Mar 27, 2026 | Buy | +25,450 | $19.67 | $500.60K | 690,704 |
| Philip Wagenheim Director | Mar 23, 2026 | Sale | −28,200 | $20.65 | $582.33K | 341,147 |
| Philip Wagenheim Director | Mar 20, 2026 | Sale | −36,800 | $20.47 | $753.30K | 369,347 |
| Jean Jacques Bienaime Director | Mar 11, 2026 | Buy | +1,000 | $21.55 | $21.55K | 38,415 |
| Jean Jacques Bienaime Director | Mar 10, 2026 | Buy | +1,000 | $22.12 | $22.12K | 37,415 |
| Clay B. Siegall President and CEO, Director | Dec 30, 2025 | Buy | +4,729 | $21.15 | $100.02K | 665,254 |
| Isaac Barchas Director | Dec 22, 2025 | Sale(10b5-1 plan) | −11,251 | $22.34 | $251.35K | 2,031,181 |
| Isaac Barchas Director | Dec 22, 2025 | Sale(10b5-1 plan) | −371,949 | $21.72 | $8.08M | 2,042,432 |
| Jack Higgins Chief Scientific Officer | Dec 19, 2025 | Gift | +1,000 | – | – | 1,000 |
| Jack Higgins Chief Scientific Officer | Dec 19, 2025 | Gift | −1,000 | – | – | 38,729 |
| Jack Higgins Chief Scientific Officer | Dec 19, 2025 | Gift | −1,000 | – | – | 39,729 |
| Jack Higgins Chief Scientific Officer | Dec 19, 2025 | Gift | −1,000 | – | – | 37,729 |
| Jack Higgins Chief Scientific Officer | Dec 19, 2025 | Gift | +1,000 | – | – | 1,000 |
| Jack Higgins Chief Scientific Officer | Dec 19, 2025 | Gift | +1,000 | – | – | 1,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Immunome's stock actually held short. Settlement fails (shares not delivered on time) peaked at 30,220 shares on Oct 7, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jack Higgins Officer | Sep 11, 2026 | 13,200 | $334.22K | Sep 11, 2026 | Stock Option Exercise |
| Isaac Barchas Director | Aug 12, 2026 | 11,048 | $301.06K | Aug 12, 2026 | Investment Distribution |
| Abhmc Ii, LLC Shareholder | Aug 6, 2026 | 108,504 | $2.77M | Aug 6, 2026 | Private Placement |
| Kinney Horn Officer | Aug 4, 2026 | 90,616 | $2.27M | Aug 4, 2026 | Stock Option Exercise |
| Kinney Horn Officer | Jul 7, 2026 | 1,092 | $27.30K | Jul 7, 2026 | Stock Option Exercise |
| Abhmc Ii, LLC Shareholder | Jul 6, 2026 | 100,000 | $2.36M | Jul 6, 2026 | Private Placement |
| Abhmc Ii, LLC Shareholder | Jul 2, 2026 | 100,000 | $2.15M | Jul 2, 2026 | Private Placement |
| Robert Lechleider Officer | Jul 2, 2026 | 55,000 | $1.19M | Jul 2, 2026 | Stock Option Exercise |
| Arsenal Bridge Venture II-B, LLC Shareholder | Jun 30, 2026 | 1,050 | $22.09K | Jun 30, 2026 | Private Placement |
| Abhmc Ii, LLC Shareholder | Jun 30, 2026 | 100,000 | $2.10M | Jun 30, 2026 | Private Placement |
| Robert Lechleider Officer | Jun 25, 2026 | 55,000 | $1.09M | Jun 25, 2026 | Stock Option Exercise |
| Max Rosett Officer | Jun 15, 2026 | 60,000 | $1.12M | Jun 15, 2026 | Stock Option Exercise |
| Max Rosett Officer | Apr 3, 2026 | 65,000 | $1.43M | Apr 2, 2026 | Stock Option Exercise |
| Jack Higgins Officer | Apr 2, 2026 | 9,438 | $204.24K | Apr 2, 2026 | Stock Option Exercise |
| Max Rosett Officer | Apr 2, 2026 | 65,000 | $4.72M | Apr 2, 2026 | Stock Option Exercise |
See a number that looks wrong?